Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
ELISA Kit for Cluster Of Differentiation 40 Ligand (CD40L)
CD154; TRAP; HIGM1; IGM; IMD3; TBAM; T-BAM; TNFSF5; Gp39; TNF Superfamily Member 5; Hyper-IgM Syndrome; TNF-Related Activation Protein; T-Cell B-Cell Activating Molecule
- Product No.SEA119Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample TypeSerum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Range0.156-10ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.057ng/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
- FOB
US$ 441
For more details, please contact local distributors! US$ 630 US$ 2835 US$ 5355 US$ 44100
Specificity
This assay has high sensitivity and excellent specificity for detection of Cluster Of Differentiation 40 Ligand (CD40L).
No significant cross-reactivity or interference between Cluster Of Differentiation 40 Ligand (CD40L) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Cluster Of Differentiation 40 Ligand (CD40L) and the recovery rates were calculated by comparing the measured value to the expected amount of Cluster Of Differentiation 40 Ligand (CD40L) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 97-105 | 101 |
EDTA plasma(n=5) | 83-99 | 87 |
heparin plasma(n=5) | 97-104 | 101 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Cluster Of Differentiation 40 Ligand (CD40L) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Cluster Of Differentiation 40 Ligand (CD40L) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Cluster Of Differentiation 40 Ligand (CD40L) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 91-105% | 98-105% | 95-102% | 80-105% |
EDTA plasma(n=5) | 80-94% | 87-95% | 80-94% | 79-97% |
heparin plasma(n=5) | 97-105% | 90-104% | 96-104% | 80-92% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
Standard | 2 | Standard Diluent | 1×20mL |
Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
GIVEAWAYS
INCREMENT SERVICES
- Single-component Reagents of Assay Kit
- Lysis Buffer Specific for ELISA / CLIA
- Quality Control of Kit
- ELISA Kit Customized Service
- Disease Model Customized Service
- Serums Customized Service
- TGFB1 Activation Reagent
- Real Time PCR Experimental Service
- Streptavidin
- Fast blue Protein Stain solution
- Single-component Reagents of FLIA Kit
- Streptavidin-Agarose Beads
Magazine | Citations |
Basic Research in Cardiology | Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation PubMed: 22899170 |
Molecules | The Protective Effects of Alisol A 24-Acetate from Alisma canaliculatum on Ovariectomy Induced Bone Loss in Vivo Pubmed:26760992 |
Journal of Neuroinflammation | Th17-skewed immune response and cluster of differentiation 40 ligand expression in canine steroid-responsive meningitis-arteritis, a large animal model for neutrophilic meningitis. pubmed:28114998 |
BMC Nephrology | Renal effects of metallothionein induction by zinc in vitro and in vivo pubmed:28302075 |
Toxicology and Applied Pharmacology | Effects of diisononyl phthalate on osteopenia in intact mice pubmed:28893586 |
INTERNATIONAL JOURNAL OF CARDIOLOGY | Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation Pubmed: 30857843 |
Available at SSRN 3335365 | Evaluating the Platelet Activation Related to the Degradation of Biomaterials by Scheme of Molecular Markers |
Data in Brief | Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation |
journal of thoracic and cardiovascular surgery | Evaluating Platelet Activation Related to the Degradation of Biomaterials Using Molecular Markers Pubmed: 32812629 |
Thrombosis Research | Feasibility study of use of rabbit blood to evaluate platelet activation by medical devices Pubmed: 31838449 |
Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study Pubmed: 32085544 |
Persistently higher serum sCD40L levels are associated with mortality in septic patients | |
Journal of Orthopaedic Translation | Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-¦ÊB and MAPK activation 33981577 |
Bioactive Materials | Secretions from hypochlorous acid-treated tumor cells delivered in a melittin hydrogel potentiate cancer immunotherapy 34820587 |